June 15, 2021
Business News

Kronos Bio Appoints Elena Ridloff, CFA, to Board of Directors

SAN MATEO, Calif. & CAMBRIDGE, Mass.–()–Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that the company has appointed Elena Ridloff, CFA, to its Board of Directors, where she will serve as Chair of the Audit Committee. Ms. Ridloff brings nearly 20 years of experience in the biopharmaceutical sector, serving in senior leadership positions in corporate finance and investor relations, including a decade spent as an institutional investor covering the healthcare industry.

“Elena is a seasoned executive with deep financial and…

Click here to view the original article.

Related Posts

You might also like ...

As Spinnaker Community Grows, Armory’s Deployments Accelerate by Simplifying Implementations
Riassunto: Equinor assegna alla Subsea Integration Alliance un contratto di fornitura di servizi di progettazione, approvvigionamento, costruzione e installazione per il progetto Bacalhau
iNitrile’s Journey to Redefine PPE Safety in the U.S Boosted by $33 Million Investment